• BIBR 1532: Telomerase Inhibitor Workflows for Cancer Researc

  2026-06-12

  BIBR 1532, a selective telomerase inhibitor from APExBIO, empowers researchers to dissect telomere biology and drive apoptosis in cancer models using robust, reproducible workflows. Leverage protocol-centric insights and troubleshooting strategies to enhance telomerase activity assays and cancer cell proliferation inhibition platforms.

• Syringin in Bioactive Compound Research: Mechanisms, Assay O

  2026-06-12

  Explore Syringin, a high-purity natural product, through the lens of advanced mechanism studies and protocol optimization. This article offers unique insights into assay design and translational relevance, setting Syringin apart in natural product research.

• Rotigotine Modulates Bladder Function in Parkinson’s Disease

  2026-06-11

  This study elucidates how the dopamine D1/D2 receptor agonist rotigotine influences lower urinary tract function in a 6-OHDA-induced rat model of Parkinson’s disease. The findings demonstrate route- and dose-dependent effects on micturition parameters, highlighting implications for both motor and non-motor symptom management in PD research.

• MG-132 (Z-LLL-al): Protocol Optimization for Apoptosis and A

  2026-06-11

  Explore how MG-132 (Z-LLL-al) enables robust apoptosis, cell cycle arrest, and autophagy workflows. This article delivers evidence-backed protocol enhancements, troubleshooting strategies, and insights from the latest research—empowering reproducible and insightful results in cancer and plant cell studies.

• SMYD2 Inhibition Reduces Cisplatin-Induced Renal Fibrosis an

  2026-06-10

  This study demonstrates that pharmacological inhibition of SMYD2, using agents such as LLY-507, protects against cisplatin-induced renal fibrosis and inflammation in a chronic kidney disease model. The findings provide mechanistic insight into SMYD2’s role in renal pathology and highlight its potential as a therapeutic target in fibrotic kidney disease.

• Deferiprone in Experimental Iron Modulation: Protocols & Ins

  2026-06-10

  Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) delivers precise, reproducible iron chelation for dissecting iron-dependent signaling in cancer, metabolism, and neurovascular models. This guide details cutting-edge workflows, troubleshooting tactics, and actionable lessons from recent metabolomics research to maximize assay success.

• E-4031 in Cardiac Electrophysiology: hERG Blocker Workflows

  2026-06-09

  E-4031 stands out as a benchmark hERG potassium channel blocker, enabling high-fidelity proarrhythmic substrate modeling and QT interval analysis in advanced cardiac electrophysiology. This article details protocol enhancements, troubleshooting strategies, and practical translation of radiotracer innovations to optimize experimental outcomes.

• Merbromin as a Protein–Ligand Interaction Probe: Workflows &

  2026-06-09

  Merbromin (Mercury dibromofluorescein disodium salt) stands out as a dual-purpose fluorescent probe and enzyme inhibition reagent, empowering quantitative binding, conformation, and antiviral assays. This article translates the latest mechanistic findings into practical, optimized workflows for biochemical research, with troubleshooting tips and strategic outlooks.

• GLT-1 Upregulation Mitigates TBI via CB1-CREB Pathway Inhibi

  2026-06-08

  This study uncovers how upregulation of GLT-1 in astrocytes reduces neuronal apoptosis and cognitive impairment after traumatic brain injury (TBI) by inhibiting the CB1-CREB signaling pathway. The findings elucidate a mechanistic link between endocannabinoid signaling, glutamate homeostasis, and neuroprotection, presenting a potential therapeutic avenue for TBI intervention.

• Fenofibrate Activates PPARα-YAP Pathway for Liver Growth in

  2026-06-08

  This study demonstrates that fenofibrate, a PPARα agonist, consistently induces liver enlargement in both adult and aging mice by activating the PPARα-YAP signaling pathway. The findings clarify that the hepatic response to fenofibrate is independent of aging, providing valuable insight for metabolic and aging research.

• Metabolic Strategies Enhance Ferroptosis and Cuproptosis in

  2026-06-07

  The referenced study introduces a nanosystem-based metabolic intervention that synchronously augments ferroptosis and cuproptosis in tumor cells by inhibiting glycolysis and NAD+ metabolism. This dual-pathway approach not only increases the susceptibility of malignant cells to regulated cell death but also enhances anti-tumor immunity, offering a robust method for improving cancer therapy outcomes.

• (R,S)-Anatabine: Applied Workflows for Neurodegeneration Res

  2026-06-06

  (R,S)-Anatabine provides a targeted strategy for soluble Aβ peptide reduction in both in vitro and in vivo Alzheimer's disease models. This article delivers detailed protocols, troubleshooting advice, and comparative insights, empowering translational researchers to maximize the compound’s potential in neurodegeneration research.

• RITA (NSC 652287): Redefining Tumor Cytotoxicity Assays in C

  2026-06-05

  Explore how RITA (NSC 652287) transforms tumor cytotoxicity analyses in cancer biology, bridging advanced in vitro evaluation with translational relevance. This article presents a unique, evidence-driven perspective on optimizing assay design for selective p53 activation.

• MOG (35-55) Peptide: Benchmark Tool for Autoimmune Encephalo

  2026-06-05

  MOG (35-55) is a validated myelin oligodendrocyte glycoprotein peptide that enables robust modeling of experimental autoimmune encephalomyelitis (EAE), the gold-standard preclinical model for multiple sclerosis research. Its use is supported by strong evidence for reproducibility, specificity, and relevance to human neuroinflammation.

• Tailored CAR Macrophage Programming via mRNA-LNP for Solid T

  2026-06-04

  Gu et al. introduce a macrophage-targeted mRNA lipid nanoparticle (LNP) system enabling in situ programming of chimeric antigen receptor (CAR) macrophages to treat peritoneal metastases. This innovation systematically evaluates CAR intracellular domains, revealing mechanisms that enhance antitumor immunity and synergize with checkpoint blockade, with direct implications for translational cancer immunotherapy research.

454 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page